Completed

WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults

WeDosify Real-World Evidence: Evaluating a Clinical Decision Support and Patient Engagement Tool for Personalized Semaglutide Dosing in Adults With Overweight or Obesity in the United States

Lead sponsor

Closed Loop Medicine

Asset

Semaglutide

GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

Study population

Obesity / overweight

Eligibility highlights

Primary endpoint

•Discontinuation due to AE

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07216651

Org study IDCLM-OB-001

Timeline

Milestones

Study start2025-09-23actual

Study first posted2025-10-14actual

Primary completion2026-02-27actual

Study completion2026-03-18actual

Last update posted2026-03-19actual

Assets

Investigational agents

Semaglutide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

Adults with Obesity or Overweight receiving semaglutide (Wegovy)

Inclusion criteria

1. Participants must be 18 years or older.

2. Participants must have a diagnosis of either obesity or overweight.

3. Participants must have initiated first-time semaglutide treatment within the past 4-12 weeks for the management of overweight or obesity, in line with United States Prescribing Information (USPI) and the clinical judgment of the responsible Healthcare Professional (HCP).

4. Participants must have access to and be able to use suitable weighing scales to record their weight before or during consultations.

5. Participants must provide written informed consent to participate in this study, including agreeing to adhere to the associated procedures.

Exclusion criteria

1. Participants with conditions that the Healthcare Professional (HCP) deems would prevent effective use of weighing scales and accurate self-monitoring or reporting of body weight.

2. Failure to satisfy the responsible Healthcare Professional (HCP) of fitness to participate for any other reason.

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Patient-reported / QoL

Safety / tolerability / PK

Weight & body composition

1 endpoint

Secondary/protocol endpoint

Weight loss from baseline to end of study

Time frame:3 months

Body weight, % change

percent change from baseline, improvement

Patient-reported / QoL

2 endpoints

Secondary/protocol endpoint

Patients' experience of WeDosify and perceived impact of treatment using custom Patient-Reported Experience Measure (PREM) and Patient-Reported Outcome Measure (PROM) questionnaires at end of study

Time frame:3 months

descriptive

Secondary/protocol endpoint

Healthcare Professional (HCP) user experience and perceived utility assessed by custom questionnaire at end of study (to include utilization and ease of use)

Time frame:3 months

descriptive

Safety / tolerability / PK

2 endpoints

Primary/protocol endpoint

Percentage of participants who persisted on semaglutide treatment over the study period

Time frame:3 months

Discontinuation due to AE

threshold achievement, improvement

Secondary/protocol endpoint

Number and percentage of participants discontinuing semaglutide due to unwanted side effects or other clinically significant reasons

Time frame:3 months

Discontinuation due to AE

threshold achievement, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.